Liisa Bayko
Stock Analyst at Evercore ISI Group
(3.66)
# 802
Out of 5,124 analysts
78
Total ratings
57.81%
Success rate
28.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Liisa Bayko
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENTA Enanta Pharmaceuticals | Maintains: Outperform | $20 → $12 | $15.77 | -23.91% | 5 | Sep 15, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $510 → $475 | $453.36 | +4.77% | 19 | Sep 11, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $280 → $515 | $397.65 | +29.52% | 2 | Sep 11, 2025 | |
| SVRA Savara | Maintains: In-Line | $3 → $2 | $6.03 | -66.83% | 5 | May 28, 2025 | |
| CRSP CRISPR Therapeutics AG | Upgrades: Outperform | $60 → $99 | $52.44 | +88.79% | 2 | Feb 14, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $33 → $45 | $38.21 | +17.77% | 5 | Feb 12, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Outperform | $10 → $12 | $7.80 | +53.85% | 5 | Jan 13, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $7 → $5 | $2.05 | +143.90% | 5 | Dec 16, 2024 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $30 → $35 | $41.25 | -15.15% | 4 | Oct 30, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $405 → $360 | $582.34 | -38.18% | 9 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $7 → $2 | $1.14 | +75.44% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $60 → $80 | $23.00 | +247.83% | 8 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $13.09 | +37.51% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $25 | $3.61 | +592.52% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $5.45 | +542.20% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $24 | $50.64 | -52.61% | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $30 | $18.71 | +60.34% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $10 | $4.81 | +107.90% | 1 | Feb 5, 2020 |
Enanta Pharmaceuticals
Sep 15, 2025
Maintains: Outperform
Price Target: $20 → $12
Current: $15.77
Upside: -23.91%
Vertex Pharmaceuticals
Sep 11, 2025
Maintains: Outperform
Price Target: $510 → $475
Current: $453.36
Upside: +4.77%
Alnylam Pharmaceuticals
Sep 11, 2025
Maintains: Outperform
Price Target: $280 → $515
Current: $397.65
Upside: +29.52%
Savara
May 28, 2025
Maintains: In-Line
Price Target: $3 → $2
Current: $6.03
Upside: -66.83%
CRISPR Therapeutics AG
Feb 14, 2025
Upgrades: Outperform
Price Target: $60 → $99
Current: $52.44
Upside: +88.79%
Travere Therapeutics
Feb 12, 2025
Maintains: Outperform
Price Target: $33 → $45
Current: $38.21
Upside: +17.77%
BioCryst Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $10 → $12
Current: $7.80
Upside: +53.85%
Editas Medicine
Dec 16, 2024
Maintains: Outperform
Price Target: $7 → $5
Current: $2.05
Upside: +143.90%
Kiniksa Pharmaceuticals International,
Oct 30, 2024
Maintains: Outperform
Price Target: $30 → $35
Current: $41.25
Upside: -15.15%
Madrigal Pharmaceuticals
Aug 8, 2024
Maintains: Outperform
Price Target: $405 → $360
Current: $582.34
Upside: -38.18%
May 16, 2024
Maintains: In-Line
Price Target: $7 → $2
Current: $1.14
Upside: +75.44%
Jun 6, 2023
Upgrades: Outperform
Price Target: $60 → $80
Current: $23.00
Upside: +247.83%
Mar 28, 2023
Initiates: Outperform
Price Target: $18
Current: $13.09
Upside: +37.51%
Jan 18, 2023
Maintains: Outperform
Price Target: $14 → $25
Current: $3.61
Upside: +592.52%
Nov 23, 2021
Initiates: Outperform
Price Target: $35
Current: $5.45
Upside: +542.20%
Jun 8, 2021
Initiates: Outperform
Price Target: $24
Current: $50.64
Upside: -52.61%
Nov 24, 2020
Reinstates: Outperform
Price Target: $30
Current: $18.71
Upside: +60.34%
Feb 5, 2020
Upgrades: Market Outperform
Price Target: $10
Current: $4.81
Upside: +107.90%